Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
Last trade$17.33
Day change+$1.05 (+6.45%)
Day range$15.25 – $17.83
Volume259,473
Market cap$678M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for APMD.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for APMD.
Recent news
Company coverage with links to the original publishers.
The obstructive sleep apnea (OSA) therapeutic landscape is rapidly expanding with 18+ companies developing 22+ pipeline drugs across multiple mechanisms of action. Eli Lilly's ZEPBOUND (tirzepatide) became the first FDA-approved pharmacological treatment for OSA in December 2024. Other major players including Apnimed, Amgen, Mosanna Therapeutics, and Incannex Healthcare are advancing late-stage candidates targeting weight loss, neuromuscular function, and airway control through diverse delivery methods.
Apnimed, Inc. (Nasdaq: APMD) closed its upsized IPO on August 3, 2026, raising $220.8 million gross proceeds by selling 13.8 million shares at $16.00 per share, including full exercise of underwriters' overallotment option. The late-stage clinical pharmaceutical company is focused on developing novel oral therapies for sleep-related breathing diseases, with its lead candidate AD109 having completed two Phase 3 trials for obstructive sleep apnea treatment and a PDUFA goal date of February 28, 2027.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.